The 70/30 Rule between Men and Women - Disparity or Opportunity? - Reply

Roxana Mehran; Jaya Chandrasekhar; Marie Claude Morice

doi:10.1001/jamacardio.2020.6136

The 70/30 Rule between Men and Women - Disparity or Opportunity? - Reply

Roxana Mehran, Jaya Chandrasekhar, Marie Claude Morice

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	482-483
Number of pages	2
Journal	JAMA Cardiology
Volume	6
Issue number	4
DOIs	https://doi.org/10.1001/jamacardio.2020.6136
State	Published - Apr 2021

Access to Document

10.1001/jamacardio.2020.6136

Cite this

@article{4ae990c8e5794c24a63be9ffee22bf15,

title = "The 70/30 Rule between Men and Women - Disparity or Opportunity? - Reply",

author = "Roxana Mehran and Jaya Chandrasekhar and Morice, \{Marie Claude\}",

note = "Funding Information: AstraZeneca, Pfizer, and Abbott Vascular and consulting fees from Quark Pharmaceuticals, Abbott Vascular, Daiichi Sankyo, Philips, Servier Laboratories, and Janssen Pharmaceuticals. Dr Sabatine reports research grant support through Brigham and Women{\textquoteright}s Hospital from Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Intarcia Therapeutics, The Medicines Company, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, and Takeda and has consulted for Althera Pharmaceutical, Amgen, Anthos Therapeutics, AstraZeneca, Bristol Myers Squibb, CVS Caremark, DalCor, Dr Reddy{\textquoteright}s Laboratories, Dyrnamix, Esperion Therapeutics, IFM Therapeutics, Intarcia Therapeutics, Janssen Research and Development, The Medicines Company, MedImmune, Merck, and Novartis. The TIMI Study Group has received institutional research grant support through Brigham and Women{\textquoteright}s Hospital from Abbott Laboratories, Amgen, Aralez Pharmaceuticals, AstraZeneca, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo, Eisai, GlaxoSmithKline, Intarcia Therapeutics, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, and Zora Biosciences. 1. Bergmark BA, O{\textquoteright}Donoghue ML, Murphy SA, et al. An exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER trial. JAMA Cardiol. 2020;5(6):709-713. doi:10.1001/jamacardio. 2020.0728 2. O{\textquoteright}Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483-1492. doi:10. 1161/CIRCULATIONAHA.118.037184 3. Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. JAm Coll Cardiol. 2019;73(17):2150-2162. doi:10.1016/j.jacc.2019.01.070",

year = "2021",

month = apr,

doi = "10.1001/jamacardio.2020.6136",

language = "English",

volume = "6",

pages = "482--483",

journal = "JAMA Cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "4",

}

TY - JOUR

T1 - The 70/30 Rule between Men and Women - Disparity or Opportunity? - Reply

AU - Mehran, Roxana

AU - Chandrasekhar, Jaya

AU - Morice, Marie Claude

N1 - Funding Information: AstraZeneca, Pfizer, and Abbott Vascular and consulting fees from Quark Pharmaceuticals, Abbott Vascular, Daiichi Sankyo, Philips, Servier Laboratories, and Janssen Pharmaceuticals. Dr Sabatine reports research grant support through Brigham and Women’s Hospital from Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Intarcia Therapeutics, The Medicines Company, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, and Takeda and has consulted for Althera Pharmaceutical, Amgen, Anthos Therapeutics, AstraZeneca, Bristol Myers Squibb, CVS Caremark, DalCor, Dr Reddy’s Laboratories, Dyrnamix, Esperion Therapeutics, IFM Therapeutics, Intarcia Therapeutics, Janssen Research and Development, The Medicines Company, MedImmune, Merck, and Novartis. The TIMI Study Group has received institutional research grant support through Brigham and Women’s Hospital from Abbott Laboratories, Amgen, Aralez Pharmaceuticals, AstraZeneca, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo, Eisai, GlaxoSmithKline, Intarcia Therapeutics, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, and Zora Biosciences. 1. Bergmark BA, O’Donoghue ML, Murphy SA, et al. An exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER trial. JAMA Cardiol. 2020;5(6):709-713. doi:10.1001/jamacardio. 2020.0728 2. O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483-1492. doi:10. 1161/CIRCULATIONAHA.118.037184 3. Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. JAm Coll Cardiol. 2019;73(17):2150-2162. doi:10.1016/j.jacc.2019.01.070

PY - 2021/4

Y1 - 2021/4

UR - https://www.scopus.com/pages/publications/85098725427

U2 - 10.1001/jamacardio.2020.6136

DO - 10.1001/jamacardio.2020.6136

M3 - Letter

C2 - 33377914

AN - SCOPUS:85098725427

SN - 2380-6583

VL - 6

SP - 482

EP - 483

JO - JAMA Cardiology

JF - JAMA Cardiology

IS - 4

ER -